Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15973049 | 0.85 | RIPK1 (0.46) | RIPK1IDO1AGXTMRGPRX4GRM5 | |
| SCHEMBL7519709 | 0.84 | ADRB1 (0.37) | IDO1MAPT | |
| SCHEMBL7271843 | 0.83 | BLM (0.58) | RIPK1IDO1AGXTMAPTMAOB | |
| SCHEMBL6340955 | 0.83 | BLM (0.58) | RIPK1IDO1AGXTMAPTMAOB | |
| SCHEMBL6340957 | 0.83 | BLM (0.58) | RIPK1IDO1AGXTMAPTMAOB | |
| SCHEMBL1812512 | 0.82 | RIPK1 (0.44) | RIPK1IDO1AGXTL3MBTL1MAOB | |
| SCHEMBL5182240 | 0.82 | IDO1 (0.42) | IDO1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5184215 | 0.82 | IDO1 (0.42) | IDO1MAPTRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12614913 | 0.82 | BLM (0.45) | MAPTTAAR1 | |
| SCHEMBL1812510 | 0.82 | RIPK1 (0.44) | RIPK1IDO1AGXTL3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102119153-A | Method for preparation of piperazindione derivates | BASF SE | 2011-07-06 | — | — | CN | disclosed |
| US-20110144336-A1 | Method for Preparation of Piperazindione Derivatives | BASF SE (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2318379-A1 | METHOD FOR PREPARATION OF PIPERAZINDIONE DERIVATES | BASF SE (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010018067-A1 | METHOD FOR PREPARATION OF PIPERAZINDIONE DERIVATES | BASF SE (DE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144336-A1 | Method for Preparation of Piperazindione Derivatives | H1-0, H1-3, H1-2 | RIPK1 4499/4885IDO1 2103/4885AGXT 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.